Samsung Group is in talks to buy Biogen in a deal that could be worth $42 billion, the Korea Economic Daily reported Wednesday, citing investment banking sources. Biogen has been laboring to launch its controversial Alzheimer’s drug, Aduhelm, and suffering from declining revenues as generics eat away sales of its flagship multiple sclerosis drug, Tecfidera.